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&j&im. This stady sought to establisb the risk ratio for 
dty associated aitlt calciam aatagohts ia a large popala- 
tion of patients witk cbroaic awoaary arteq disease. 
&7c&n9uad.~tR?portsbavesnggestedtkattheoseof 
short* ldfedipiue lllsy cause ail illmaae in oved mortauty 
inpatieatswitkcommuyarterydiseaseaadthatasimilarelfect 
ltltlYIR?pRldUCPd$~CltkiUlittiO~~iU~~thOSe 
of the dispdrowrdine type. 
MM. Mortality data were cbtained for 11,575 patients 
sawened for the Bezatibrate Infarcfioa Freventioo study (5,843 
withaadq32withoatcaichaotagoaists)afteralsepo~. 
upperiodof3.2years. 
Results. There were 4% dfatbs (8.5%) in the calcium antago- 
nist grasp compared with 410 ia the contml gmap (7.2%). The 
For the last two decades calcium antagonists have been among 
the most widely used drugs for the treatment of angina pectoris 
and hypertension. Numerous studies have shown that calcium 
antagonists (e.g., nifedipine, verapamil, diltiazem, amlodipine 
and others) were therapeutically effective in patients with 
chronic stable angina pectoris: they not only ameliorated 
symptoms but also objectively decreased ischemia on exercise 
test, reduced ST segment changes on ambulatory electrocar- 
diographic monitoring, increased coronary artery blood flow 
and improved ventricular dysfunction associated with ischemia 
(l-4). Studies of hypertensive patients showed that cakium 
antagonists were as effective as antihypertensive agents and 
were free of many of the side effects of diuretics and beta- 
adrenergic blocking agents (5). 
Several clinical trials and meta-analyses of the clinical trials 
age-adjusted risk ratio fw mortality was 1.08 (95% conlideace 
interval [cl] 0.95 lo 1.24). After adjastmpst for the Were-aces 
betweatkegroupsinageandgeaderaadtkepmvaleaceof 
prevkmsmyafanWinfamt@aagi5a~hypwtonsioo, 
Nt~~YorkIIattA~st&tbt~Fnoeticul-!dass,peripheraim~r 
disense,chnmlcobstrsetive~di~diabetesaud 
canvntsmskingjtbeadjastedriskmtiade&iaaltoO.97(9S%C2 
0.84 to 1.11). After fhther adjustmeat f&r CoaamlItaut media- 
tioq the risk ratio was estimated at 0.94 (%% Cl 0.82 to 1.08). 
(JARI GTE tziwdbl19%;2&:7-Ii) 
of calcium antagonists in myocardia! infarction and unstable 
angina pectoris suggested that the drugs had an unfavorable 
effect on mortality (6-14). In a recent report Furberg et al. 
(15) suggested that the use of short-acting nifedipine at 
moderate and high doses may cause an increase in overall 
mortality in patients with coronary artery dii, and that a 
similar effect may be produced by otker calciwn antagonists, in 
particular those of the dihydropyridine type. Because long 
term safety data are lacking for most calcium antagonists the 
aim of the present study was to estimate the risk ratio for 
mortality associated with calcium antagonists in a large popu- 
lation of patients with chronic coronary artery disease, 70% of 
whom had at least one previous my~dii infarction. Data 
were collected in patients screened for participation in the 
Berafihmte Infarction Prevention (BIP) study (16). 
Between February 1, i990, and October 30,1!7!2, clii 
datawmorethan2o,ooOmaleandfemalepatientsaged4Sto 
74yearsandpnamiedtohawcotvnmyarterydiseasewere 
reaudedintbelogboohsof18cardiidepartmemsin 
Israel. A total of 15,502 patients with an esmbkkd diagnosis 
ofL9lrc&auonaryartery~were-forhriusitm 
073WV7&15.00 
Pu so73s4o?7(wi)tanas-x 
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in the BiP study, and they comprised the population in the BIP 
registry. The BIP study (la), a placebocontrolled, secoridary 
prevention study, is currently being conducted on 3,122 pa- 
tients in ‘18 cardiology departments in Israel with the aim of 
assessing the e&acy of the long-term administration of beza- 
fibrate on the reduction of fatal and nonfatal coronary events 
in patients with coronary artery disease. 
All the patients screened for the BIP study underwent a 
medical examination and a blood test after fasting for 14 h. 
Medical, historical and drug intake data were recorded. The 
diagnosis of coronary artery disease was made in patients with 
documented m;?cardial infarction or typical angina pectoris in 
whom there was also a positive exercise test, evidence of 
myocardial ischemia revealed by radionuclear studies or at 
least 60% stenosis of one major coronary artery. Patients who 
had undergone percutaneous transluminal coronary angio- 
piasty or coronaty artery bypass grafting were considered for 
study entry if the procedure had been performed at least 6 
months before inclusion into the study. 
The current analysis is restricted to the patients who had 
been screened but had not been included in the BIP study. 
Mortality data on 11,575 of the 15,502 screenees, after a mean 
follmv-up period of 3.2 years (range 2.0 to 4.6), were obtained 
by matching the patients’ identitication number with their lie 
status in the Israeli Population Registry. Death certificates and 
diagnosis at hospital discharge were coded using the system 
described in the ninth edition of the International Chsification 
ofDirease (ED-g), in which coronary artery disease is denoted 
by codes 410 to 414. 
Statist&al metbads. Results of continuous variables are 
reported as mean value ? SD. The chi-square and Student t 
tests were used to determine the significanw of differences 
between proportions and means, respectively. The adjusted 
relative risk of mortality associated with calcium antagonist use 
was estimated using the Cox proportional hazards model (17). 
The stati&al power of detecting clinically meaningful diier- 
ences with a mortality rate of 7.2% in nomtsers of calcium 
aatagonists was 0.90, under a type 1 error of 0.05 and an odds 
ratio as large as 1.25 (corresponding to a mortality rate of 
-9.2% in calcium . ..qonist users). The power declined 
progressively to 0.74,0.50 and 0.030, with declining odds ratios 
of 1.2, 1.15 and 1.1. 
Results, 
and clinkal elurackristics. Table 1 sum- 
marks the characteristica of patients being treated with 
calcimn antagonists compared with those not receiving the 
drugs (control subjects). At Wscreening visit, 5,843 patients 
were treated with either nifedipine, verapamil or dihiazem, the 
only c&km antagonks approved in Israel at that time. The 
control group mnsisted of 5,732 patients who did not receive 
cakiumantagonist~ciinkaileristicsofbothgroups 
were similar, except that there were more patients with gradea 
~‘tOWCUlghptXt0&tUId~*lLSiOtlhltheCakiUUl 
antago& group and more patients in the control group were 
Table 1. Baseline Clinical Characteristics of 11,575 Study Patients 
Calcium Antagonist Group Control Group 
(n = 5,843) (n = 5,732) 
Age w 60.4 59.2 
Weight (kg) 152 12 15-t 12 
Systolic BP (mm Hg) 137 t 19 133 + 19 
Diastolic BP (mm Hg) 82 ?r 10 81 ? IO 
Hean rate (beatdmin) 715 10 71 2 10 
Me!! 75 82 
NYHA functional class 
I bb lb 
11 27 19 
IllilV 7 5 
History of MI 70 12 
Current angina (CCS) 
None 30 49 
1 32 34 
II 34 19 
III/TV 4 2 
Hypertension 38 29 
Diabetes mellitus 23 20 
CVA 2.2 1.5 
PVD 5 3 
COPD 3.6 2.5 
Current smoker 10 II 
DN& therapy 
Beta-blockers 29 39 
Digmin 3 7 
Diuretic drugs 16 16 
Ant&rhythmic agents 5 1 
As&in 56 58 
Data presented are mean value, meao value 2 SD or number (%) of 
patients. BP = blood p’wore; CCS = Canadian Cardiiar sofiex 
COPD = chronic ohstmctive pulmonary disease; CVA = cerebral vascolar 
accident; MI = myocardial infarction; NYHA = New York Heart Asswiation; 
PVD = peripheral vascular disease. 
receiving beta-blockers and digoxin. The clinical characteristics 
of the 3,122 patients included in the BIP study were simi& to 
the 11,575 pa:ients not recruited for the BIP study, except that 
there were more men (92%), more patients who had had a 
myocardial infarction (77%) and fewer patients suffering from 
diabetes meltitus (10%). 
Moetality rates in users and llonllsers of aakium antago- 
nists. Table 2 summarizes the mortality figures in both groups. 
There were 495 (8.5%) deaths in the calcium antagonist group 
compared with 410 (7.2%) deaths in the control group. The 
age-adjusted risk ratio (RR) for mortality was 1.08 (95% 
confidence interval [CI] 0.95 to 1.24). After adjustment for the 
differences between the groups in age and gender and the 
prevalence of previous myocardiil infarction, angina pectoriq 
hypertension, New York Heart Association functional class, 
peripheral vascular disease, chronic obstructive pulmonary 
dkeass, diabetes and current smoking, the RR dedined to 0.97 
(%% CI 0.84 to 1.11) (Table 3). On further adjustment for the 
ahove-mentioned charaderistics, the calculation of the RR for 
the different subgronps was c4&stent with a signiitiy 
iocreasedmmtalityriskforpatients<55yearsofageinthe 
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Tabte 2. Calcium Antagonists and Age-Adjusted Mortality: 
subgroup Aualysii 
MOZtdily 
calc.tual Aatagottist contml 
Group Group RR (95% CI) 
Total 
MetI 
WOm.2ll 
Past MI 
NOMI 
Hypertension 
No hypcrtettsion 
Diabetes 
No diabetes 
PVD 
NO PVD 
COPD 
No COPD 
NYHA functional class 
I 
n 
~(Ccs, 
NOW 
I 
II 
Innv 
Smoker 
Current 
Past 
NftW 
4% (8.5) 410 (7.2) 1.08 (0.95-1.24) 
390 (8.9) 331(7.0) 1.18 (1.02-136) 
105 (7.1) 79 (7.6) 0.83 (0.62-1.12) 
401(9.8) 337 (8.2) 1.11 (O.%-1.28) 
92 (5.3) 72 (45) 1.06 (0.78-1.44) 
212 (9.5) 139 (8.4) 1.09 (O&3-1.35) 
Bl(7.8) 271 (6.7) 1.04 (0.88-1.24) 
178 (13.3) 146 (12.7) 0.98 (0.79-1.22) 
316 (7.0) 264 (5.8) 1.10 (0.94-1.30) 
46 (15.9) 43 (22.2) 0.65 (0.43-1.00) 
442 (8.0) 355 (6.6) l.lO(O.%-1.27) 
35 (16.7) 25 (17.6) 0.87 (0.52-1.46) 
451(8.2) 383 (6.9) 1.08 (0.94-1.24) 
289 (7.7) 
135 (8.9) 
60 (14.2) 
232 (55) 1.30(1.09-154) 
120 (11.7) 0.68 (053-0.86) 
4.4 (15.8) 0.76 (0.52-1.13) 
’ 38 (7.8) 
136 (7.2) 
191(9.7) 
29 (13.7) 
59 (9.7) 
256 (85) 
175 (8.0) 
154 (5.5) 1.29 (1.02-1.63) 
120(7@) 0.94 (0.74-1.20) 
109 (10.2) 0.88 (0.69-1.11) 
22 (21.2) 0.54 (0.31-0.94) 
58 (95) 0.93 (0.64-133) 
189 (6.5) 1.22 (1.01-1.47) 
155 (7.3) 1.00 (0.80-1.24) 
Data presented are mmher (%) of patients. Cl = a&dence intetv& RR = 
risk ratio; other abbreviations as in Table 1. 
calcimn antagonist group, for patients without angina pectoris 
and for patients in the functional class I, ahhougb the 95% CI 
included “1” for aU these subgroups. Conversely, it was con- 
sistent with reduced mortality for the patients with a functional 
class higher than I and for those with anejna pectoris. On 
further adjustment for concomitant use of other medications 
(beta-blockers, aspirin, nitrates and diuretic drugs) the RR was 
not markedIy altered-O.94 with a 95% CI 0.82 to 1.08. 
Of the 5,843 patients treated with calcium antagonists, 
3,320 received dihiazem (57%), 1,999 nifedipine (34%) and 
350 verapamil (6%). In addition, 174 patients (3%) were 
treated with a combiiation of two cakiurn antagonists. The 
mortality rates for the three single cakium antagonist groups 
were 8.0%, 8.8% and 8.6% respectively (the differences were 
not signhicant) (Table 4). 
Discussion 
InIsraelcalciumantagonistsareannmgthe.most~ 
used N for patients with V disease. Fii 
perccntofthepatientasmeenedfortbeBIPstudywere 
re&vingoneofthetbmecaIciumanmgonismappmvedin 
IsraeIforthetreaunentofanginapecto&sorhypertension 
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Table 3. Calcium Antagonists aad Mortality, Adjusted for Age, 
Gender, Previous Myocardial Infarction, Angina, New York 
Heart Association Functional Class, Hypertension, Peripheral 
Vascular Disease, Chronic Obstructive Pulmonary Disease, Diabetes 
and Current Smoking 
Mortahty 
Calcium Amagoaist Clmtrol 
Gr0Llp GYP RR (95% c;) 
Total 
Men 
Women 
Age w 
<55 
55-64 
65-75 
Past MI 
No MI 
Hypertensim 
NC ~pxtensim 
Diabetes 
No diabetes 
NYHA-alclass 
1 
II 
llHv 
Aagina WV 
NOM 
1 
II 
IILTV 
495 (8.5) 
3% (8.9) 
105 (7.1) 
69 (5.8) 
191 (7.1) 
235 (12.0) 
401(9.8) 
92 (53) 
212 (95) 
281(7.8) 
178 (133) 
316 (7.0) 
239 (7.7) 
135 (8.9) 
60 (14.2) 
138 (7.8) 
136 (7.2) 
191(9.7) 
29 (13.7) 
410 (7.2) 0.97 (0.84-1.11) 
331(7.0) 1.01 (0.86-1.18) 
79 (7.6) 0.87 (0.64-1.18) 
55 (3.5) 139 (O.%-201) 
178 (7.2) 0.82 (0.67-I 02) 
177 (10.6) 1.05 (0.86-1.29) 
337 (82) 0.98 (0.84-1.14) 
72 (4.5) 0.94 (0.68-1.30) 
139 (8.4) 1.03 (0.82-1.28) 
271 (6.7) 0.94 (0.79-K) 
146 (12.7) 0.89 (0.7i-1.12) 
264 (5.8) 1.04 (0.87-I 24) 
232 (55) 1.19(099-1.42) 
120 (11.7) 0.68(0x-0.86) 
4.4 (15.8) O.a1(054-1.21) 
154 (55) 1.21(0.95-155) 
120 (7.0) 0.92 (0.72-1.18) 
109 (10.2) OsofO.66-1.07) 
22 (21.2) 058 (0.32-1.06) 
The mortality analysis over a period of 3.2 years showed d 
slightly greater mortahty in the calcium antagonist group; 
however, because of the different preva.Iencea of some ciinical 
characteristics between the groups, an additionaI anaIysii was 
performed to adjust stat&icaUy for these differences. The 
second analysii eliminated the mortahty Merenor between 
the two groups. An attempt was made to identify subgroups in 
whii treatment may have been harmful zd othw in wtti& it 
may have been beneti&I. The amdysis of the rnortahty in the 
varioussubgoupsreveaIedatrendtowardmoredeatbsamong 
patients <55 years of age, patients with coronary artery disease 
but without dinii angina pectoris and patients in fu&onaI 
dam 1. GmverseIy, rnortabty of patients in fun&mai dass >I 
and of patients with angina pec@nis was lower when they were 
treated with a cakitnn antagonist. These anaIy~~ shotdd be 
Tab#c 4 D&r&ion of Various Calcium Antagonists 
lwedi@ 
Vaspsnjl 
Ditliwm 
1,999 04) 
350 (6) 
33200 
174(3) 
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interpreted with caution because they have not yet been 
verified in a randomized, prospective trial. Moreover, exami- 
nation of the effects of treatment in multiple subgroups 
increases the possibility of observing extreme results by chance. 
No difference in mortality was noted between the nifedipine, 
verapami! and diltiazem groups in this study. 
Comparison witb previous studies. In their recent study, 
Furberg et a!. (15) concluded that short-acting nifedipine in 
moderate to high doses may cause an increase in overall 
mortality. However, the data they cite show no significantly 
increased risk at doses of 30 to 60 mg/day, thus their conclusion 
was drawn on a dose of 80 mg/day, which is unusually high for 
nifedipine. In the early 9Os, most patients in Israel were treated 
with 30 to 60 mg of short-acting nifedipine. Thus. our obser- 
vational results are in full agreement with the experimental 
ones from other studies (l&19) of patients in the chronic stage 
of their coronary artery disease. In thtse studies the 6-month 
mortality rate was similar for the aifedipine and control 
patients. 
It had been previously pointed out that implicating a wide 
range of calcium antagonists on the basis of several studies 
with short-acting nifedipine is unjustified (20-22). Indeed, two 
studies suggested that verapami! (7) and diltiazem (11) have 
been efficacious in reducing mortality in certain patient groups. 
It is a!so questionable to make judgments on the safety and 
elcacy of antihypertensive treatment with a new generation of 
calcium antagomsts using data from studies on previous gen- 
erations of calcium antagonists. These are currently being 
examined in c!iica! trials (23). 
Study IImitatlons. We have tried to address the recent and 
ongoing heated controversy over the use of calcium antagonists 
in patients with carrV~~~~~!ar disease (20,22X5). We are 
aware of the obvious limitations of conducting an observa- 
tiona! analysis ori groups with different characteristics and 
statistically adjusting for the differences, rather than judging an 
effect of medication on mortality (24) in a randomized clinibal 
trial. In addition to the observational nature of our results, we 
have relied on a single report of fherapy for each patient made 
available to us during a screening examination. Certainly, 
therapy may undergo several changes, even within a relatively 
short fo!!ow-up period. We assumed that crossover between 
the three calcium antagonists was limited and that, rather than 
discontinuing the medication, any major changes that might 
have been made would probabiy entail the addition of new 
drugs such as arigiotensin-amverting enzyme inhibitors. 
Despite these !iitatiom, the results we derived from a 
!arge number of patients with chronic coronary artery disease 
may be a meaningful contribution to the recent discussion on 
the safety of ca!cinm antagonists in patients with coronav 
artexy d&se. 
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results consistently failed to show an association between 
calcium antagonist theraW and mortality. Routine prophylac- 
tic treatment with calcium antagonists of patients during the 
acute phase of myocardia! infarction has never been indicated. 
T!ms, calcium antagonists should be reserved for clear-cut 
clinical indications. The current analysis does not support the 
claim that calcium antagonist therapy in patients with izoronaty 
artery disease, whether myocardia! infarction survivors or 
others, harbors an increased risk of mortality. 
Appendix 
Participating Centers and Investigators for the 
Bezafibrate Infarction Prevention Study Group 
8ekntifie eommlttee: Jacob Agmon, MD, Solomon Behar, MD, Daniel 
Brunner. MD (Chairman). Avraharn Caspi, MD, Uri Goldhourt. PhD, Eran 
Gratf, PhD, Eliir Kaplinsky, MD, Yehezkiel Kishon, MD, Henrietta Reicher- 
Reiss MD. Joshua Wavshort. MD 
Schlesinger, MD, Ah&on Fried&&, MD. B&aihf&& C&q 
4shkelon: Leonardo R&in, MD, Jamal Jafari, MD. Bei5mon iwe&a/ Coua, 
Pernch 7iiah: Yaacov Friedman, MD, Samuel Sclamvsky, MD, bruno Gstfefd, 
MD. En&Zion Hospi&f, Ha@: Edward Abiider, MD, Shmuel Rochlleii, MD. 
Carmel Hospi&l, Hoifo: Abraham Palant, MD, Hanan Schneider, MD. CerumJ 
Emek Hospiud, A&la: Tiberiu Rosenfeld, h%D, Suleiman Khalid, MD. lX/h 
Wdfsoon .&&cd Cmrm, Hokm: Yehezkiel Kishon, MD, Ron Narinsky, MD, 
Rene Rot& t&D. H&won Hos$a& Perach i’Xv& lzhar Zahavi, MD, Janash 
Vitrai, MD. Hillel Yafi Hospiral H&m: Benyamin Pelfed, MD, Joseph Pardu, 
MD. Ichfiov tfospitol, Somrky h4ea?cal Cmrm, Tel Aviv: Shloma Laniido, MD, 
L&i Sherf, MD, Shiion Braun, MD, Yemima E&char, MD. Kaplan Hosrpiur 
Reti Avraham Caspi, MD, Alexander Arditi, MD, Shulamit Botwin, MD. 
Me& HospitrJ Sapir 1wW Cemer, Kfar Saba: Daniel David, MD, Daniel 
W&se&q, MD. N&aria Hoapiu~ Nakati Nathan Roguin, MD, Malka 
Yahalom, MD, Alicia Glwman, MD. Rambarn Medicxzl Cewr, Ha@: Vladimir 
Markiewic& MD, Diav M&k, MD. Rivka Ziv Haspi& Z#: Michael Flich, 
MD, Alon Marmour, MD. Shaare Z&k btedical Cent@, Jemsalnn: Monty Zion, 
MD, Jonathan Balkin, MD. Sheba Medical Centi Hean Inwhue, Tel HM 
Baheth Rahinowitt MD, Eddy Bamscb, MD. Son&a Medical &-n&r, Bee&w: 
Moshe Gueron, MD, Natalio K&al, MD. 
Ctmeh&m. After an average follow-up period of 3.2 
years, patients treated with calcium antagonists exhibited a 
Slig!U, statisticaI!y tiom@Smt increase in morta!ity com- 
pared wi& cxMrol wbjects Multivariate at&y& adjusting for 
variaMesthatrelIectthec!inicalseverityofcoronaryartety 
diseaseeliianyindicationofincreasedriskThese 
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